A Phase I Study of Atezolizumab Immunotherapy Given with Cisplatin during Radiation Therapy for Locally Advanced Cervical Cancer

Print

Full Title

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer (CIRB)

Purpose

Cisplatin chemotherapy and radiation therapy are standard treatments used together for newly diagnosed locally advanced cervical cancer, but not all patients benefit. In this study, researchers are evaluating different dosing schedules of the immunotherapy drug atezolizumab added to cisplatin and radiation therapy in patients with locally advanced cervical cancer. Atezolizumab boosts the ability of the immune system to find and kill cancer cells.

Patients will be randomly assigned to one of two treatment groups which differ according to when they receive atezolizumab during their course of therapy. Atezolizumab and cisplatin are each given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have newly diagnosed locally advanced cervical cancer.
  • Patients may not have received radiation therapy to the abdomen or pelvic region, nor any systemic cancer therapy (chemotherapy, immunotherapy, or radiation therapy) in the three years prior to the study.
  • Patients may not have a history of autoimmune disease.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for women age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Dmitriy Zamarin at 646-888-4882.

Protocol

19-054

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators